Anadys Shareholders Challenge $230M Sale To Roche
Anadys Pharmaceuticals Inc. shareholders on Monday targeted the company's leadership along with Swiss drug giant Roche Holdings Inc. in a proposed class action accusing the two drugmakers of undervaluing Anadys stock...To view the full article, register now.
Already a subscriber? Click here to view full article